Comparative Pharmacology
Head-to-head clinical analysis: TRILYTE versus XPHOZAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRILYTE versus XPHOZAH.
TRILYTE vs XPHOZAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRILYTE (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, ascorbic acid) is an osmotic laxative. The active components induce diarrhea by osmotically drawing water into the gastrointestinal lumen, thereby increasing stool volume and stimulating peristalsis. Sodium ascorbate and ascorbic acid enhance the osmotic effect.
XPHOZAH (tenapanor) is a sodium-hydrogen exchanger 3 (NHE3) inhibitor. It acts locally in the gastrointestinal tract to inhibit NHE3, reducing sodium and phosphate absorption, leading to decreased serum phosphate levels.
Adults: 1 liter (L) orally every 10-15 minutes until 4 L total consumed; complete ingestion within 4 hours.
10 mg orally three times daily (TID) with or without food.
None Documented
None Documented
Not applicable; non-absorbed, acts locally in GI tract
Terminal elimination half-life is approximately 14 days, supporting monthly subcutaneous dosing for sustained serum phosphate reduction.
Renal excretion of intact electrolyte ions; negligible drug excretion
Primarily eliminated in feces (approximately 92%) as unchanged drug; renal excretion is negligible (<1%).
Category C
Category C
Laxative
Laxative